Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias
{"title":"利用监测、流行病学和最终结果项目数据库,2015年至2020年肺癌、乳腺癌、结直肠癌和前列腺癌的治疗起始时间及其影响因素","authors":"Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias","doi":"10.14740/wjon2519","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.</p><p><strong>Methods: </strong>We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.</p><p><strong>Results: </strong>Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.</p><p><strong>Conclusion: </strong>Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 2","pages":"152-160"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954607/pdf/","citationCount":"0","resultStr":"{\"title\":\"Time to Treatment Initiation of Lung, Breast, Colorectal, and Prostate Cancers and Contributing Factors From 2015 to 2020 Utilizing Surveillance, Epidemiology, and End Results Program Database.\",\"authors\":\"Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias\",\"doi\":\"10.14740/wjon2519\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.</p><p><strong>Methods: </strong>We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.</p><p><strong>Results: </strong>Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.</p><p><strong>Conclusion: </strong>Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.</p>\",\"PeriodicalId\":46797,\"journal\":{\"name\":\"World Journal of Oncology\",\"volume\":\"16 2\",\"pages\":\"152-160\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954607/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/wjon2519\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Time to Treatment Initiation of Lung, Breast, Colorectal, and Prostate Cancers and Contributing Factors From 2015 to 2020 Utilizing Surveillance, Epidemiology, and End Results Program Database.
Background: The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.
Methods: We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.
Results: Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.
Conclusion: Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.
期刊介绍:
World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.